ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany
ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
The innovaTV 301 study results fulfill the post-marketing requirement of the previous accelerated approval
NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in Patients with mUC
Frequent occurrence of NECTIN4 amplifications in other cancer types is promising for development of NECTIN4-targeted antibody drug conjugates in a tumour-agnostic context
Early Stage Triple-negative Breast Cancer: Hot Topics and Future Trends 2024
08 May 2024
Chair: Peter Schmid
Speakers: Oleg Gluz, Peter Schmid, Aditya Bardia